Scientists at St. Jude  Children’s Research Hospital studied how common and rare genetic variants influence late-onset cardiomyopathy...

Updated guidance for managing cardiovascular toxicity in patients treated for childhood cancer has been provided in a scientific...

A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...

Being born with a heart defect may be associated with an increased cancer risk for babies and their moms, according to new research...

For children battling both congenital heart defects (CHD) and cancer, the road to recovery is far more precarious than previously...

Findings from scientists at St. Jude Children's Research Hospital are showing promise for assessing cardiomyopathy risk in childhood...

The link is not uncommon: ‘Cardiotoxicity’ is a major side effect of anticancer treatments. Read more: https://www.washingtonpost.com/wel...

Although more than 85% of childhood cancer survivors will achieve a 5-year survival, that does not tell the whole tale for these...

New research out of VCU Massey Comprehensive Cancer Center and VCU Health Pauley Heart Center indicates that survivors of childhood...

In a U.S./Canadian phase IIb trial (PREVENT-HF) reported in The Lancet Oncology, Armenian et al found that the beta-blocker carvedilol...